WO2021215039A1 - Méthode et dispositif d'évaluation d'absorbabilité orale de médicament - Google Patents

Méthode et dispositif d'évaluation d'absorbabilité orale de médicament Download PDF

Info

Publication number
WO2021215039A1
WO2021215039A1 PCT/JP2020/044362 JP2020044362W WO2021215039A1 WO 2021215039 A1 WO2021215039 A1 WO 2021215039A1 JP 2020044362 W JP2020044362 W JP 2020044362W WO 2021215039 A1 WO2021215039 A1 WO 2021215039A1
Authority
WO
WIPO (PCT)
Prior art keywords
simulated
drug
gastrointestinal
chamber
fluid
Prior art date
Application number
PCT/JP2020/044362
Other languages
English (en)
Japanese (ja)
Inventor
山下　伸二
片岡　誠
晴輝 東野
敏英 高木
Original Assignee
学校法人常翔学園
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人常翔学園 filed Critical 学校法人常翔学園
Priority to JP2021521458A priority Critical patent/JP7090272B2/ja
Publication of WO2021215039A1 publication Critical patent/WO2021215039A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Definitions

  • the present invention relates to a method and an apparatus for accurately evaluating the absorption of an orally administered drug from the digestive tract.
  • the test preparation which is a newly prepared preparation
  • the standard preparation which is an existing preparation, that is, to meet the BE test, for oral preparations
  • the drug after administration of the preparation The difference between the maximum blood concentration (Cmax) and the area under the blood concentration-time curve (AUC) calculated from the transition of the blood concentration of the drug by measuring the blood concentration of the drug over time is within a certain range. It is required to be.
  • Cmax is an index of drug absorption rate
  • AUC is an index of drug absorption.
  • the preparation first stays in the stomach, where the disintegration of the preparation and the elution of the drug from the preparation begin.
  • the drug moves from the stomach to the small intestine while eluting the drug.
  • the eluted drug is also dissolved and absorbed in the solution in the stomach and small intestine while migrating in the same manner.
  • the drug is hardly absorbed from the stomach, so absorption begins when the drug is transferred to the small intestine.
  • the pH of the solution changes from acidic pH to neutral pH with the transition from the stomach to the small intestine, so that the drug in the solution dissolves or reprecipitates according to the pH.
  • the profile of dissolution / precipitation in the gastrointestinal tract greatly affects the absorption rate and amount of the drug. Furthermore, the effective surface area of the small intestinal mucosa involved in absorption from the small intestine increases with time as the solution is transferred, which affects the drug absorption rate particularly immediately after the start of absorption. Therefore, in order to accurately evaluate the difference in drug absorption rate and absorption amount between pharmaceutical products in vitro, it is necessary to construct a system that can reproduce the above-mentioned in vivo behavior of the pharmaceutical product in the gastrointestinal tract. be.
  • Non-Patent Document 1 uses a liquid feeding pump to sequentially feed a drug-containing liquid to a plurality of vessels simulating the stomach, duodenum, and jejunum, and the accompanying changes over time such as dissolution, dissolution, and precipitation of the drug.
  • the system for observing ((Gastrointestinal Simulator (GIS))
  • GIS Gastrointestinal Simulator
  • the degree of mechanical crushing of the pharmaceutical particles during liquid feeding and the difference in the moving speed between the pharmaceuticals affect the evaluation result. It also differs from the human gastrointestinal tract in that it is difficult to move insoluble particles. Furthermore, since GIS does not include the process of membrane permeation, it is not possible to evaluate the actual amount of absorption. In addition, it is necessary to construct a complicated and expensive system including a computer system for controlling the liquid property and movement of the liquid in the vessel. In addition, due to the slow throughput, it takes a considerable amount of time to evaluate many test products.
  • Non-Patent Document 2 the test drug is added to the solution in the gastrointestinal chamber and stirred by using a device in which the gastrointestinal chamber and the blood vessel chamber are connected via a small intestinal epithelial cell model membrane, and the small intestine is stirred.
  • a system Dissolution Permeation System (D / P system)) for measuring the concentration of a drug that has permeated the epithelial cell model membrane and transferred to the solution in the vascular chamber is described. Since the D / P system measures the concentration of the drug that has permeated the membrane, it is suitable for evaluating the amount of drug absorbed.
  • D / P system Dissolution Permeation System
  • the D / P system uses a solution with a certain composition such as a solution that imitates the stomach or a solution that imitates the small intestine as the solution in the gastrointestinal chamber, the solution composition due to the movement of the drug in the gastrointestinal tract It is not possible to reproduce changes in the environment such as pH. In addition, the increase in the effective drug absorption area of the small intestinal mucosa due to drug transfer cannot be reproduced. Therefore, it is not possible to reproduce the time course of drug elution, dissolution, and absorption in actual human in vivo. In particular, it is difficult to accurately evaluate the difference in absorption rate (Cmax) between formulations.
  • Cmax absorption rate
  • Patent Document 1 uses a device in which a vascular chamber in which a part of the chamber wall is composed of a gastrointestinal model membrane is housed in a gastrointestinal vessel in which a rotating paddle is installed, and is used as a solution in the gastrointestinal vessel.
  • a system In vitro Dissolution Absorption System 2 (IDAS2)
  • IDAS2 is suitable for evaluating the amount of drug absorbed because it measures the concentration of the drug that has permeated the membrane after the drug has been eluted from the drug.
  • An object of the present invention is to provide a method and an apparatus capable of accurately evaluating the absorbability (absorption rate and absorption amount) of a drug into systemic circulating blood after oral administration of a drug or a drug-containing preparation to humans. do.
  • the present inventor repeated research in order to solve the above problems, and put a drug or a drug-containing preparation into a simulated gastrointestinal solution (a solution adjusted by imitating the composition and pH of the solution in the digestive tract) to perform simulated digestion.
  • the drug in the tubule is permeated into the simulated blood through the drug permeable membrane, and in the simulated gastrointestinal tract fluid and / or in the simulated blood (a solution adjusted to imitate the composition and pH of the blood or a solvent such as octanol).
  • a simulation of the injection of the drug or the drug-containing preparation is performed.
  • the gastrointestinal fluid is used as a simulated gastric fluid (a solution adjusted by imitating the composition and pH of the solution in the stomach), and the liquidity and composition of the simulated gastrointestinal fluid are used to simulate the environmental change from the stomach to the small intestine.
  • the volume is changed from simulated gastric fluid to simulated small intestinal fluid (solution adjusted by imitating the composition and pH of the solution in the small intestine) at an arbitrary speed, and the contact area between the simulated gastrointestinal fluid and the drug permeable membrane. It has been found that a method of increasing the amount of water over time can solve the above-mentioned problems.
  • the state of the simulated gastrointestinal fluid such as liquidity, composition, and volume is changed from the stomach to the small intestine over time to create an environment in the gastrointestinal tract where the drug actually administered to humans is placed. It can be reproduced. Therefore, the disintegration of the pharmaceutical product, the elution and dissolution of the drug in the human gastrointestinal tract can be accurately reproduced.
  • the drug that has moved from the stomach to the small intestine has a larger contact area with the mucous membrane of the small intestine as it moves in the small intestine, and the drug absorption rate increases accordingly.
  • AUC absorption amount of the drug
  • Cmax absorption rate of the drug
  • a drug or a drug-containing preparation is put into a simulated gastrointestinal fluid, and the drug in the simulated gastrointestinal fluid is permeated into the simulated blood through a drug permeable membrane, and the simulated gastrointestinal fluid and / or the simulated blood is used. It is a method of evaluating the oral absorbability of an orally administered drug or a drug in a preparation by measuring the drug concentration, in which the state of simulated gastrointestinal fluid is changed from the stomach to the small intestine over time, and at the same time.
  • a method for evaluating oral drug absorption which comprises increasing the contact area between a simulated gastrointestinal fluid and a drug permeable membrane over time.
  • a gastrointestinal chamber for accommodating simulated gastrointestinal fluid which is provided with a simulated gastrointestinal fluid pool at the bottom and has a mechanism for injecting concentrated simulated small intestinal fluid inside, and the inside of the gastrointestinal chamber is stirred.
  • the simulated gastrointestinal fluid to be generated is stirred while injecting the concentrated simulated small intestinal fluid into the simulated gastric fluid by the concentrated simulated small intestinal fluid injection mechanism.
  • a vascular chamber for accommodating simulated blood which is connected to the gastrointestinal chamber at a drug-permeable connection located above the simulated gastric fluid pool, is used, and a drug-permeable membrane is formed on the surface of the drug-permeable connection.
  • the gastrointestinal chamber and the vascular chamber are separated from each other by being installed so that the direction is inclined with respect to the horizontal direction, and the concentrated simulated small intestinal juice is injected into the simulated gastric juice by the concentrated simulated small intestinal juice injection mechanism.
  • the method according to [2] wherein the liquid level of the generated simulated gastrointestinal fluid is raised to increase the contact area between the simulated gastrointestinal juice and the drug permeable membrane over time.
  • the vascular chamber is provided with a mechanism for injecting simulated blood into the inside, and by using this infusion mechanism, the height of the liquid level in the gastrointestinal chamber is matched with the height of the liquid level in the vascular chamber.
  • the drug concentration in the simulated gastrointestinal fluid and / or the drug concentration in the simulated blood is measured over time to simulate the initial drug concentration increase rate in the simulated gastrointestinal fluid and / or the initial drug concentration increase rate in the simulated blood.
  • [6] The method according to any one of [1] to [5], wherein the state of the simulated gastrointestinal fluid that undergoes changes over time is pH, composition, and volume.
  • It has a gastrointestinal tract chamber and a vascular chamber, and a simulated gastrointestinal fluid pool is provided at the bottom of the gastrointestinal tract chamber. It is connected by a connection part, and the drug permeable connection part is installed so that the surface direction of the drug permeable membrane is inclined with respect to the horizontal direction to separate the gastrointestinal tract chamber and the vascular chamber.
  • the gastrointestinal chamber is provided with an inlet for injecting concentrated simulated small intestinal fluid
  • the vascular chamber is provided with an inlet for injecting simulated blood inside, and the simulated gastrointestinal fluid is housed in the gastrointestinal chamber.
  • a drug oral absorption evaluation device which comprises a stirrer for agitating.
  • An automatic liquid feeding device for injecting concentrated simulated small intestinal juice from the injection port of the gastrointestinal chamber and / or an automatic liquid feeding device for injecting simulated blood from the injection port of the vascular chamber is provided [7].
  • the device described in. [9] (a) A device that automatically samples simulated gastrointestinal fluid and / or simulated blood, (b) A device that automatically samples simulated gastrointestinal fluid and / or simulated blood and automatically applies it to a drug measuring device. Or (c) equipped with an automatic monitoring device that automatically samples simulated gastrointestinal fluid and / or simulated blood, automatically applies it to a drug measuring device, and automatically measures the drug concentration by the drug concentration measuring device, [7] or [ 8]. [10] 7. Device.
  • the method of the present invention is by gradually changing the environment (simulated gastrointestinal fluid) in which the drug or the drug-containing preparation is placed after oral administration from the stomach to the small intestine without moving the drug or the drug-containing preparation. , It is possible to accurately reproduce the disintegration of the pharmaceutical product and the elution and dissolution of the drug when orally administered to humans.
  • the method of the present invention reflects the increase in the effective absorption area of the small intestinal mucosa due to the movement of the drug in the human gastrointestinal tract by increasing the contact area between the simulated gastrointestinal fluid and the drug permeable membrane over time. It is possible to evaluate the drug absorption. This makes it possible to accurately evaluate not only the amount of drug absorbed but also the rate of absorption. Therefore, AUC and Cmax can be predicted with high accuracy at the same time.
  • information on the disintegration, dissolution, dissolution, and absorption process of the pharmaceutical product after oral administration to humans can be sufficiently verified before the human BE test. can. Therefore, unnecessary clinical trials can be avoided, the number of subjects in clinical trials can be reduced, or the success rate of clinical trials can be increased.
  • the pH and composition of the simulated gastrointestinal tract fluid can be arbitrarily changed. For example, if the pH is changed from 1.6 to 6.5 over about 10 minutes, the environment becomes similar to the movement of the drug taken during fasting from the stomach to the small intestine. In addition, for example, if the pH is changed from 5 to 6.5 over about 30 minutes, the environment becomes similar to the movement of the preparation taken at the time of feeding from the stomach to the small intestine. Therefore, according to the method of the present invention, oral absorbability under various conditions such as fasting and feeding can be evaluated.
  • the evaluation can be performed according to the subject by adjusting the composition of the simulated gastrointestinal fluid. Further, when examining the change of the formulation, the enteric formulation, the sustained release formulation, etc. can be easily examined by arbitrarily changing the pH and composition of the simulated gastrointestinal fluid.
  • the volume of the simulated gastrointestinal tract fluid affects the drug elution rate.
  • the pharmaceutical product administered to humans moves in the digestive tract, the amount of liquid in the surroundings changes.
  • the volume of the simulated gastrointestinal fluid can be arbitrarily changed, the behavior of elution and dissolution of the drug in the human gastrointestinal tract can be accurately evaluated.
  • the elution property of the drug is controlled by additives, coatings, layer structures, etc., the elution behavior of the pharmaceutical product cannot be evaluated if it is divided according to the volume of the simulated gastrointestinal fluid.
  • the volume of the simulated gastrointestinal tract fluid can be arbitrarily changed to approximate the volume of the human gastrointestinal tract fluid, the oral absorbability of not only the drug but also the drug-containing preparation is evaluated. can do.
  • the method of the present invention does not require a complicated and expensive device because the state of the simulated gastrointestinal fluid can be changed only by controlling the injection rate of the concentrated simulated small intestinal juice.
  • results can be obtained in a short time of about 60 to 120 minutes for one sample.
  • the device of the present invention is a simple and inexpensive device capable of carrying out the method of the present invention having such features.
  • FIG. 1 It is a figure which shows one example of the apparatus of this invention. It is a figure which shows the elution rate and the membrane permeability of metoprolol tartrate from 20 mg of Seroken (registered trademark) tablet. It is a figure which shows the elution rate and the membrane permeability of telmisartan from a telmisartan (registered trademark) tablet under the fasting condition. It is a figure which shows the elution rate and the membrane permeability of telmisartan from a telmisartan tablet under the condition at the time of feeding. It is a figure which shows the human BE test result between the standard preparation under the fasting condition and the preparation A.
  • the pH was changed over a longer period of time than the method shown in Fig. 14. It is a figure which shows the elution rate and the membrane permeability of dipyridamole from a persantin tablet under the fasting condition. The pH at the start is higher than the method shown in Figures 13-15.
  • a drug or a drug-containing preparation is put into a simulated gastrointestinal tract fluid, and the drug in the simulated gastrointestinal tract fluid is permeated into the simulated blood through a drug permeable membrane.
  • a method for evaluating the oral absorbability of an orally administered drug or a drug in a preparation by measuring the drug concentration in the simulated gastrointestinal fluid and / or the simulated blood. This method is characterized in that the contact area between the simulated gastrointestinal fluid and the drug-permeable membrane is increased over time while changing from to the inside of the small intestine over time.
  • the formulations are solid formulations such as tablets, powders, granules, pills and capsules (soft capsules, hard capsules); liquid formulations such as liquids, elixirs, suspensions, emulsions, limonades and syrups. It may be either.
  • a single dose may be added to the simulated gastrointestinal tract fluid.
  • the input amount may be determined according to the purpose of the test.
  • Examples of the "state" of the simulated gastrointestinal fluid that undergoes changes over time include pH, composition, volume, and the like.
  • the simulated gastrointestinal fluid at the time of adding the drug or the drug-containing preparation may be simulated gastric juice. Since the pH of human gastric juice is about 1 to 3 during fasting and about 2 to 6 after eating, the pH of simulated gastric juice should be about 1 to 3 when evaluating oral absorbability during fasting. , When evaluating the oral absorbability at the time of feeding, it should be about 2 to 6.
  • the pH can be adjusted by using a buffer solution such as an acetate buffer solution.
  • the simulated gastric juice may contain a digestive enzyme such as pepsin, sodium chloride, or the like, whereby the simulated gastric juice can be made to resemble a human gastric juice.
  • the volume of simulated gastric juice should be about 20 to 250 mL, especially about 50 to 200 mL.
  • the volume of gastric fluid in human adults is about 20 to 50 mL, and solid preparations are often taken with water except for orally rapidly disintegrating tablets (in clinical trials, they are taken with 150 mL of water). If it is within the range, the evaluation can reflect the dissolution rate of the drug in the human stomach.
  • the drug may be dissolved by stirring the simulated gastric juice, or the drug-containing preparation may be disintegrated to dissolve the drug.
  • the state of the simulated gastrointestinal fluid may be gradually brought closer to that of the human small intestinal fluid by gradually injecting the concentrated simulated small intestinal juice into the simulated gastric juice containing the drug.
  • the simulated gastrointestinal fluid may be agitated while injecting the concentrated simulated small intestinal juice.
  • the concentrated simulated small intestinal juice referred to here is for approximating the composition of the simulated gastrointestinal fluid to the simulated small intestinal juice by adding it to the simulated gastric juice, and its composition, addition amount, addition timing, etc. meet this purpose. Specific examples thereof include, but are not limited to, the following. Since the pH of human small intestinal juice is about 6 to 8, the pH of concentrated simulated small intestinal juice may be about 6.5 to 10.
  • the pH can be adjusted by using a buffer solution such as a carbonate buffer solution, a Tris / HCl buffer solution, a HEPES buffer solution, or a phosphate buffer solution.
  • a buffer solution such as a carbonate buffer solution, a Tris / HCl buffer solution, a HEPES buffer solution, or a phosphate buffer solution.
  • the pH of the simulated gastrointestinal fluid can be finally adjusted to about 6-8.
  • the concentrated simulated small intestinal juice may contain bile acids, lipids, sugars, digestive enzymes such as glycolytic enzymes, proteolytic enzymes, and lipid-degrading enzymes, thereby making the concentrated simulated small intestinal juice of humans. It can be approximated to small intestinal juice.
  • the amount of concentrated simulated small intestinal juice to be injected may be such that the amount of simulated gastrointestinal juice is finally about 50 to 500 mL, especially about 100 to 400 mL. Since the volume of the small intestinal fluid in a human adult is usually about 100 to 400 mL, an evaluation that reflects the absorption rate of the drug in the human small intestine can be performed within this volume range.
  • the injection time of the concentrated simulated small intestinal juice should be about 5 to 120 minutes, especially about 10 to 60 minutes. In the case of fasting evaluation, it may be about 5 to 20 minutes, especially about 10 minutes, and in the case of feeding evaluation, it may be about 20 to 120 minutes, especially about 30 to 60 minutes. This makes it possible to approximate the time it takes for the drug to travel from the stomach to the small intestine in actual humans.
  • the drug permeable membrane may be one in which the drug in the simulated gastrointestinal fluid permeates to the simulated blood side.
  • a cell layer membrane obtained by culturing cells, a gastrointestinal mucosa extracted from a human or non-human animal, an artificial lipid membrane, a porous membrane, and the like can be mentioned.
  • the cell layer membrane include those obtained by culturing cells in a single layer.
  • cells cultured on a porous membrane so as to form a single layer can be used together with the porous membrane.
  • the type of cell is not limited, but includes epithelial cells such as Caco-2 cells, C2BBel cells, MDCK cells, MDR-MDCK cells, BCRP-MDCK cells, HT-29 cells, and T-84 cells, especially the human small intestine.
  • Caco-2 cells which are widely used as model cells, are preferable.
  • the excised gastrointestinal membrane the small intestinal mucosa excised from humans or experimental animals such as rats, dogs, and monkeys can be used. In that case, all the excised submucosal tissues such as muscles can be used, or the submucosal tissues can be peeled off and used.
  • a phospholipid membrane or a lipid membrane formed by adding cholesterol or a membrane protein to phospholipid can be used as the artificial lipid membrane.
  • the lipid membrane can be used alone or formed on a porous membrane.
  • PAMPA Parallel Artificial Membrane Permeability Assay
  • the porous membrane (including the semipermeable membrane) preferably has a pore size of about 0.1 to 0.5 ⁇ m. Porous membranes with various pore sizes are commercially available.
  • membrane filters precision filtration membrane filters made of various materials are commercially available from Merck, and among them, Durapore (registered trademark) membrane filter (polyvinylidene fluoride membrane) and Millipore (registered trademark) filter (cellulose mixture). Ester membranes), Millipore Express Plus (polyether sulfone membranes), Isopore® membrane filters (track-etched polycarbonate membranes), hydrophobic polytetrafluoroethylene (PTFE) membranes, etc. are all available, all of which are preferred. Although it can be used, the Durapore membrane filter has less adsorption of proteins and the like, and can be particularly preferably used in the present invention.
  • a buffer solution having a pH of about 7.3 to 7.5, particularly about 7.4, which imitates blood can be used as the simulated blood.
  • the buffer solution may be any one having a buffering ability at a pH of about 7.3 to 7.5, and examples thereof include a phosphate buffer solution, a HEPES buffer solution, and a Tris / hydrochloric acid buffer solution.
  • plasma protein may be added to the simulated blood, whereby it can be approximated to human blood.
  • the drug permeable membrane is a porous membrane
  • an organic solvent such as octanol, hexane or chloroform or an oil such as olive oil
  • the biological membrane contains phospholipids as the main component, the magnitude of distributability in the oil / water two-layer system is interpreted as an index of affinity for the biological membrane. , Can mimic drug permeation from the small intestine.
  • octanol which is widely used for measuring the distributiveness of drugs, is preferable.
  • the simulated gastrointestinal fluid may be brought into contact with the drug-permeable membrane at the same time as or thereafter when the concentrated simulated small intestinal juice is started to be infused, and the contact area thereof may be gradually increased. This makes it possible to reproduce the increase in effective small intestinal mucosal area in which the drug administered to humans can be absorbed.
  • the drug permeable membrane may bring the region corresponding to the region in contact with the simulated gastrointestinal fluid into contact with the simulated blood. Therefore, the amount of simulated blood used may be gradually increased so that the contact area with the drug permeable membrane changes in this way.
  • the final contact area between the drug-permeable membrane and the simulated gastrointestinal fluid should be about 0.5 to 20 cm 2. Therefore, a drug permeable membrane having an area of 0.5 to 20 cm 2 or larger can be used.
  • one or both of the simulated gastrointestinal fluid and the simulated blood may be sampled over time to measure the drug concentration. It is preferable to sample both simulated gastrointestinal fluid and simulated blood over time.
  • the drug concentration in the simulated blood can be plotted against the elapsed time, and Cmax, which is an index of the absorption rate or the absorption rate in vivo, can be estimated from the initial slope of the increase in the drug concentration. Although it depends on the amount of simulated gastrointestinal fluid, the size of the drug permeable membrane, etc., the slope of 10 to 60 minutes after the drug concentration starts to rise is adopted because the absorption rate or Cmax in clinical tests can be estimated accurately. It is preferable to do so.
  • the dissolution rate of the drug is an important factor that determines Cmax
  • the drug concentration in the simulated gastrointestinal fluid is plotted against the elapsed time
  • the drug dissolution rate is calculated from the initial inclination of the increase in the drug concentration, and the drug dissolution rate is obtained.
  • the speed can be taken into account in the estimation of Cmax. It is preferable to adopt a slope of 10 to 60 minutes after the drug concentration begins to rise.
  • the amount of drug absorbed or AUC which is an index thereof, can be estimated from the amount of drug permeation (or membrane permeability) up to a certain period of time.
  • the gastrointestinal chamber may be used to store the simulated gastrointestinal fluid.
  • the upper surface of the gastrointestinal chamber may be open or covered with a lid.
  • a simulated gastric juice pool may be provided at the bottom of the gastrointestinal chamber.
  • the drug or drug-containing preparation is added to the simulated gastric juice placed in the simulated gastric juice pool, the state in which the drug or preparation has moved into the stomach is reproduced.
  • the capacity of the simulated gastric juice pool may be about 20 to 250 mL, especially a capacity that can accommodate about 50 to 200 mL of simulated gastric juice.
  • the total volume of the gastrointestinal chamber including the simulated gastric juice pool may be about 50 to 500 mL, particularly about 100 to 400 mL, as long as it can accommodate the simulated gastrointestinal fluid.
  • the gastrointestinal chamber may be provided with a mechanism for injecting concentrated simulated gastrointestinal fluid into the inside.
  • the injection mechanism may include, for example, an injection port provided in the gastrointestinal chamber and an automatic liquid delivery device.
  • the inlet may be provided on the upper surface or the side surface of the gastrointestinal chamber, but the provision on the side surface, particularly on the side surface of the upper end of the simulated gastric juice pool, is excellent in reproducibility of the state in the human small intestine.
  • Examples of the automatic liquid feeding device include those provided with a tube connected to an injection port and a liquid feeding pump.
  • the liquid feed pump may be one that can keep the liquid feed rate constant or change it as planned.
  • the concentrated simulated small intestinal fluid infusion mechanism operates by adjusting the infusion rate and amount so that the state of the simulated gastrointestinal fluid reflects the movement of the drug or preparation taken by humans from the stomach to the small intestine. Is.
  • a mechanism for stirring the simulated gastrointestinal fluid in the gastrointestinal chamber may be used.
  • This stirring mechanism may be capable of stirring the simulated gastric juice and the simulated gastrointestinal fluid obtained by injecting the concentrated simulated small intestinal juice.
  • Examples of the stirring mechanism include rotary blades or vibrating blades installed in the gastrointestinal chamber. Further, it may consist of a magnetic stirrer bar placed at the bottom of the gastrointestinal chamber and a magnetic stirrer placed outside the bottom surface of the gastrointestinal chamber.
  • the internal liquid is agitated by vibrating the gastrointestinal chamber
  • the simulated gastrointestinal liquid is agitated by ultrasonic vibration, or a gas such as air or oxygen is blown into the simulated gastrointestinal liquid.
  • the liquid may be agitated.
  • the mechanism for stirring the simulated gastrointestinal fluid is preferably a rotary blade or a vibrating blade whose stirring speed can be easily controlled.
  • Sampling of simulated gastrointestinal fluid can be done manually. Alternatively, it can be performed using a mechanism for sampling the simulated gastrointestinal fluid at a predetermined time. It is also possible to manually apply the sampled simulated digestive tract fluid to a drug concentration measuring device such as a high performance liquid chromatography device to measure the drug concentration, but the sampled simulated digestive tract fluid can be used as a drug concentration measuring device. An applying mechanism can also be used. Further, it is also possible to use an automatic monitoring device that samples the simulated gastrointestinal fluid at a predetermined time, applies it to the drug concentration measuring device, and measures the drug concentration by the drug concentration measuring device.
  • a drug concentration measuring device such as a high performance liquid chromatography device
  • a vascular chamber may be used to contain simulated blood.
  • the vascular chamber is connected to the gastrointestinal chamber via a drug permeable connection, as described below.
  • the upper surface of the vascular chamber may be open or covered with a lid.
  • the gastrointestinal chamber and the vascular chamber may be in contact with each other with a common side wall, or may be separate containers.
  • the vascular chamber may be equipped with a mechanism for stirring the simulated blood inside.
  • the stirring mechanism the same mechanism as the simulated gastrointestinal fluid stirring mechanism can be exemplified. Since the stirring rate of simulated blood does not affect the evaluation result of oral absorbability, it is convenient to use a magnetic stirrer bar placed at the bottom of the vascular chamber and a magnetic stirrer placed outside the bottom surface of the vascular chamber. ..
  • the gastrointestinal chamber and the vascular chamber are connected or communicated with a drug permeable connection in order to allow the drug in the simulated gastrointestinal fluid to permeate into the simulated blood through the drug permeable membrane.
  • the drug permeable connection is provided on the common side surface of both chambers when the gastrointestinal chamber and the vascular chamber are in common side contact, and both containers when the gastrointestinal chamber and the vascular chamber are separate containers. It is provided as a passage between them.
  • the drug permeable connection is located above the simulated gastric juice pool.
  • the lower end of the drug permeable connection is preferably located near the upper end of the simulated gastric juice pool, which allows monitoring of drug absorption immediately after the drug has moved to the small intestine.
  • a drug permeable membrane is installed at the drug permeable connection in order to allow the drug in the simulated gastrointestinal tract fluid to permeate into the simulated blood via the drug permeable membrane.
  • the gastrointestinal chamber and the vascular chamber are completely separated by a drug permeable membrane.
  • the drug permeable membrane is installed at the drug permeable connection so that its surface direction is inclined with respect to the horizontal direction. NS.
  • the drug permeable membrane is installed so that its plane direction is vertical. The drug-permeable membrane thus installed and the concentrated simulated small intestinal juice injection mechanism jointly increase the contact area between the simulated gastrointestinal fluid and the drug-permeable membrane over time.
  • the shape of the drug-permeable membrane is not particularly limited, and examples thereof include a circular shape, a quadrangular shape, a triangular shape, and a trapezoidal shape. Of these, an inverted triangle or a trapezoid whose upper side is longer than the lower side is preferable in that it approximates an increase in the effective drug absorption area of the actual human small intestine.
  • the vascular chamber is provided with a mechanism for injecting the simulated blood into the inside.
  • the infusion mechanism may include, for example, an infusion port provided in the vascular chamber and an automatic fluid delivery device.
  • the inlet may be provided on the upper surface or the side surface of the vascular chamber.
  • the automatic liquid feeding device include those provided with a tube connected to an injection port and a liquid feeding pump.
  • the liquid feed pump may be one that can keep the liquid feed rate constant or change it as planned.
  • This injection mechanism operates while adjusting the injection rate of simulated blood so that the liquid level in the gastrointestinal chamber and the liquid level in the blood vessel chamber are at the same level. This makes it possible to eliminate the effect of the difference in liquid level between the two chambers on the membrane permeation rate of the drug.
  • Sampling of simulated blood can be done manually. Alternatively, it can be performed using a mechanism for sampling simulated blood at a predetermined time. Further, the sampled simulated blood can be manually applied to a drug concentration measuring device such as a high performance liquid chromatography device to measure the drug concentration, but a mechanism for applying the sampled simulated blood to the drug concentration measuring device is provided. It can also be used. Further, it is also possible to use an automatic monitoring device that samples simulated blood at a predetermined time, applies it to a drug concentration measuring device, and measures the drug concentration by the drug concentration measuring device.
  • a drug concentration measuring device such as a high performance liquid chromatography device to measure the drug concentration
  • the method of the present invention is preferably carried out using a temperature control device that keeps the temperature of each liquid used constant.
  • the temperature control device can keep at least the temperature of the simulated gastrointestinal fluid in the gastrointestinal chamber and / or the temperature of the simulated blood in the vascular chamber constant. Since the temperature affects the elution and dissolution of the drug, it is particularly preferable that the temperature of the simulated gastrointestinal fluid in the gastrointestinal chamber can be kept constant.
  • the temperature control device include a heat medium circulation temperature control device and a heater attached to both chambers.
  • the temperature control device may also be capable of keeping the temperature of the simulated gastric juice to be injected, the concentrated simulated small intestinal juice, and the simulated blood constant.
  • a temperature control chamber accommodating all the mechanisms and members except the control device can be used.
  • the temperature of each liquid may be maintained at about 20 to 37 ° C., and above all, it may be maintained at around 37 ° C., which is the human body temperature.
  • the oral drug absorption evaluation device of the present invention has a gastrointestinal chamber and a vascular chamber, and a simulated gastric fluid pool is provided at the bottom of the gastrointestinal chamber, and the gastrointestinal chamber and the gastrointestinal chamber.
  • the vascular chamber is connected by a drug permeable connection provided above the simulated gastric pool, and the drug permeable connection is such that the drug permeable membrane is tilted with respect to the horizontal direction. It is installed in the gastrointestinal chamber to separate the gastrointestinal chamber from the vascular chamber.
  • the device is provided with an inlet and a stirrer for stirring simulated gastrointestinal fluid contained in the gastrointestinal chamber.
  • the device of the present invention can include an automatic liquid delivery device for injecting concentrated simulated small intestinal juice from the injection port of the gastrointestinal chamber and an automatic liquid delivery device for injecting simulated blood from the injection port of the vascular chamber. ..
  • the automatic liquid feeding device is as described for the method of the present invention.
  • the device of the present invention can be provided with a stirrer that agitates the simulated blood contained in the blood vessel chamber.
  • the stirrer is as described for the method of the present invention.
  • the device of the present invention can be provided with a mechanism for sampling simulated gastrointestinal fluid and / or simulated blood.
  • the sampling mechanism may automatically sample each liquid at a predetermined time (over time).
  • a mechanism for applying the sampled simulated gastrointestinal tract fluid and / or simulated blood to a drug measuring device such as a high performance liquid chromatography device can be provided.
  • a drug concentration measuring device can be provided. It is also possible to provide an automatic monitoring device that automatically samples simulated gastrointestinal fluid over time, applies it to a drug concentration measuring device, and measures the drug concentration by the drug concentration measuring device.
  • the device of the present invention preferably includes a temperature control device capable of keeping at least the temperature of the simulated gastrointestinal fluid in the gastrointestinal chamber and / or the temperature of the simulated blood in the vascular chamber constant.
  • the temperature control device may also be capable of keeping the temperature of the simulated gastric juice to be injected, the concentrated simulated small intestinal juice, and the simulated blood constant.
  • the temperature control device is as described for the method of the present invention.
  • the device comprises a gastrointestinal chamber 1 and a vascular chamber 2.
  • the lumens of both chambers are cylindrical, and the top surfaces of both chambers are open.
  • the bottom of the gastrointestinal chamber 1 constitutes a gastric juice pool 1a.
  • the height of the bottom surface of the vascular chamber is the same as the height of the upper end of the gastric fluid pool 1a.
  • the shape of the gastric juice pool 1a is substantially hemispherical here, but is not particularly limited.
  • a concentrated simulated small intestinal juice injection port 1b is provided on the upper side wall of the gastric juice pool 1a.
  • a tube 3a is connected to the concentrated simulated small intestinal juice injection port 1b so that the concentrated simulated small intestinal juice can be injected into the gastrointestinal chamber 1 using a pump 4a.
  • the gastrointestinal chamber 1 and the vascular chamber 2 communicate with each other by a drug permeable connection part 5.
  • the drug permeable connection 5 is above the gastric pool 1a.
  • a drug permeable membrane 6 is installed in the drug permeable connection portion 5, and the gastrointestinal chamber side and the vascular chamber side of the drug permeable connection portion 5 are completely separated. The drug permeable membrane 6 is installed so that its plane direction is vertical.
  • the drug permeable membrane 6 is a circular porous filter having a diameter of 47 mm (Merck Millipore, Durapore® Membrane, Type 0.22 ⁇ m PVDF Membrane).
  • the volume of the gastric juice pool 1a is 40 mL, and the volume of the gastrointestinal chamber 1 containing the gastric juice pool 1a is 100 mL.
  • a rotary stirrer 7 having stirring blades at two positions above and below is installed coaxially with the lumen of the gastrointestinal chamber. One of the stirring blades is in a position where it can stir in the gastric fluid pool, and the other is above the gastric fluid pool.
  • a magnetic stirrer 8a is installed on the outside of the bottom surface of the vascular chamber, and a magnetic stirrer bar 8b is placed on the bottom surface inside the vascular chamber.
  • a simulated blood inlet 2b is provided on the side wall of the blood vessel chamber 2.
  • a tube 3b is connected to the concentrated simulated small intestinal juice injection port 2b so that the simulated blood can be injected into the vascular chamber 2 using the pump 4b.
  • the pump 4b can control the injection rate of the simulated blood so that the height of the simulated blood in the vascular chamber 2 is the same as the height of the simulated gastrointestinal fluid in the gastrointestinal chamber 1. ..
  • This device manually samples simulated blood and simulated gastrointestinal fluid, but it may be equipped with a device that samples them over time at the required timing and a device that applies it to a drug concentration measuring device. preferable.
  • FIG. 1 An example of a method for evaluating the oral absorbability of a drug in a pharmaceutical product using the apparatus shown in FIG. 1 will be described.
  • 40 mL of simulated gastric juice during fasting is placed in a gastric juice pool, and the test preparation is added thereto for one dose.
  • the simulated gastric juice is stirred with the rotary stirrer 7 to dissolve the drug.
  • the concentrated simulated small intestinal juice is injected from the concentrated simulated small intestinal juice inlet 1b through the tube 3a at a rate of 6 mL / min.
  • the rotary stirrer 7 stirs the simulated gastrointestinal fluid produced by mixing the simulated gastric juice and the concentrated simulated small intestinal juice.
  • the simulated blood is injected into the vascular chamber 2 from the simulated blood injection port 2b via the tube 3b by driving the pump 4b so as to be at the same height as the simulated gastrointestinal fluid.
  • sampling of simulated gastrointestinal fluid was started 1 minute after the start of injection, and sampling of simulated blood was started 2 minutes after the start of injection, and then sampling was performed over time, using a high performance liquid chromatography device. The drug concentration was measured.
  • the drug concentration is plotted against time, and the slope of the graph for 45 minutes from the time when the drug concentration in the simulated blood begins to rise is used as an index of Cmax (absorption rate), and 120 minutes from the start of injection of concentrated simulated small intestinal fluid.
  • Cmax absorption rate
  • AUC absorption amount
  • the rate of drug dissolution in the gastrointestinal tract can be used as an auxiliary parameter in estimating Cmax from the rate of increase in drug concentration in simulated blood.
  • Fasted state simulated gastrointestinal fluid (pH3.0)
  • pH was adjusted to 3.0 instead of adjusting to pH 1.6 with 5 M hydrochloric acid
  • the simulated gastric juice during fasting (pH 3. 0) was prepared.
  • Pre-FaSSIF Food state simulated intestinal fluid
  • HBSS 50.028 mL Sodium bicarbonate 174.996 mg D-glucose 1250.004 mg HEPES 1125 mg Sodium taurocorate 5 mM (1092.996 mg)
  • Lecithin 1.25 mM Add the above components to an appropriate amount of McIlvaine buffer adjusted to pH 4, make a solution, and finally make up to 300 mL (step 1).
  • 40 mL of FaSSGF and 60 mL of the solution prepared in step 1 are mixed, and the pH is adjusted to 6.5 with 5 M sodium hydroxide (step 2). Record the amount of sodium hydroxide required at this time.
  • Pre-FeSSIF Pre-Fed state simulated intestinal fluid
  • Sodium bicarbonate 174.996 mg D-glucose 1250.004 mg
  • HEPES 1125 mg
  • Lecithin 6.25 mM Add the above components to an appropriate amount of McIlvaine buffer adjusted to pH 4, make a solution, and finally make up to 300 mL (step 1).
  • 40 mL of FeSSGF and 60 mL of the solution prepared in step 1 are mixed, and the pH is adjusted to 6.5 with 5 M sodium hydroxide. Record the amount of sodium hydroxide required at this time (step 2).
  • Empirical data 1 (Effect of rotation speed of rotary stirrer in gastrointestinal chamber) 40 mL (pH 1.6) of simulated gastric juice during fasting and 20 mg of Seroken tablets were placed in the gastric juice pool 1a of the gastrointestinal chamber 1 of the device shown in FIG. While stirring with the rotary stirrer 7, the fasting simulated small intestinal juice was injected into the gastrointestinal chamber 1 at a flow rate of 6 mL / min for 10 minutes to obtain 100 mL of the fasting simulated small intestinal juice having a pH of 6.5. The stirring speed by the rotary stirrer 7 was set to 50 rpm, 100 rpm, or 200 rpm. Octanol, which is simulated blood, was injected into the vascular chamber 2 at a flow rate of 2.5 mL / min over 10 minutes to obtain a final volume of 25 mL.
  • Concentrated simulated small intestinal juice is injected into the gastrointestinal chamber. Simulated gastrointestinal juice and simulated blood are sampled over time for 120 minutes from 1 minute after the start of injection, and the concentration of metprorol tartrate, which is the active ingredient of Seroken tablets, is analyzed by high performance liquid chromatography. Measured by chromatography. Furthermore, the elution rate of metoprolol tartrate from the tablets at each time point (percentage of the amount of metoprolol tartrate in the simulated gastrointestinal tract fluid at each time point to the amount of metoprolol tartrate in one tablet) (%) was calculated. In addition, the membrane permeability of metoprolol tartrate at each time point (percentage of the amount of metoprolol tartrate in simulated blood at each time point to the amount of metoprolol tartrate in one tablet) (%) was calculated.
  • Empirical data 2 (Comparison between formulations of telmisartan-containing tablets) 40 mL (pH 1.6) of simulated gastric juice during fasting or 40 mL (pH 5.0) of simulated gastric juice during feeding and 20 mg of telmisartan tablets were placed in the gastric juice pool 1a of the gastrointestinal chamber 1 of the device shown in FIG.
  • the concentrated simulated small intestinal juice during fasting was injected into the gastrointestinal chamber 1 at a flow rate of 6 mL / min for 10 minutes while stirring with the rotary stirrer 7, so that the pH was 6.5 during fasting.
  • the simulated small intestinal juice was 100 mL.
  • pH 6.5 was obtained by injecting simulated small intestinal juice during feeding into the gastrointestinal chamber 1 at a flow rate of 2 mL / min for 30 minutes while stirring with a rotary stirrer 7.
  • the simulated small intestinal juice at the time of feeding was 100 mL.
  • the stirring speed by the rotary stirrer 7 was set to 50 rpm.
  • octanol which is simulated blood, was injected into the vascular chamber 2 at a flow rate of 2.5 mL / min over 10 minutes to give a final volume of 25 mL.
  • octanol was injected into the vascular chamber 2 at a flow rate of 0.833 mL / min over 30 minutes to give a final volume of 25 mL.
  • a preparation manufactured by Boehringer Ingelheim Co., Ltd. was used as a standard preparation, and preparations A and B having different additives were used for comparison.
  • Concentrated simulated small intestinal juice is injected into the gastrointestinal chamber From 1 minute to 120 minutes, simulated gastrointestinal juice and simulated blood are sampled over time, and the concentration of thermisartan, which is the active ingredient of thermisartan tablets, is measured by high performance liquid chromatography. It was measured. Furthermore, the elution rate of telmisartan from the tablets at each time point (percentage of the amount of telmisartan in the simulated gastrointestinal fluid at each time point to the amount of telmisartan in one tablet) (%) was calculated. In addition, the membrane permeability of telmisartan at each time point (percentage of the amount of telmisartan in simulated blood at each time point to the amount of telmisartan in one tablet) (%) was calculated.
  • Empirical data 3 Comparison between oral absorption evaluation results of drug X and clinical trial results
  • the elution rate and membrane permeability of drug X from the drug X-containing preparation were measured.
  • the drug X-containing preparation the standard preparation and the preparations A and B having different additives were used.
  • the drug X concentration in plasma was measured for 12 hours.
  • the standard preparation and the test preparation were administered to the same subject with a drug holiday of 3 days or more.
  • the subject was in a sitting position from the start of administration to 4 hours after administration, and was not in a standing or lying position except at the time of examination and in the toilet.
  • the subject's drinking water was controlled from 1 hour before administration of each preparation to 4 hours after administration, except for drinking water for taking the preparation.
  • the eating conditions were a high-fat diet (900 kcal or more, and the ratio of lipid energy to total energy was 35% or more) within 20 minutes, and the preparation was administered within 10 minutes after eating.
  • Figure 5 shows the results of the BE test in humans between the standard formulation under fasting conditions and formulation A.
  • Fig. 6 shows the results of the dissolution rate and membrane permeability of drug X from the standard preparation and the preparation A under the feeding conditions.
  • the plasma concentration of drug X in the human BE test was lower for the standard preparation than the standard preparation, and the dissolution rate and the membrane permeability were lower than the standard preparation for the preparation A.
  • FIG. 7 shows the results of the BE test in humans between the standard preparation under the feeding conditions and the preparation A.
  • Fig. 8 shows the results of the elution rate and membrane permeability of drug X from the standard preparation and the preparation A under the feeding conditions.
  • the plasma concentration of drug X in the human BE test was lower for the standard preparation than the standard preparation, and the dissolution rate and the membrane permeability were lower than the standard preparation for the preparation A.
  • the difference in plasma drug X concentration between the standard preparation and the preparation A was larger during the fasting than during the fasting, which is consistent with the dissolution rate at the time of fasting. In comparison, the difference in dissolution rate between the standard preparation and the preparation A was larger when eating.
  • Figure 9 shows the results of the BE test in humans between the standard formulation under fasting conditions and formulation B.
  • the results of the elution rate and membrane permeability of the drug X from the standard preparation and the preparation B under the fasting condition are shown in FIG.
  • the plasma concentration of drug X in the human BE study was higher with the standard preparation immediately after administration, but was higher with the preparation B thereafter.
  • the dissolution rate and the membrane permeability of the preparation B were higher than those of the standard preparation.
  • the elution rate and membrane permeability results were close to those of the human BE test.
  • Figure 11 shows the results of the BE test in humans between the standard preparation under the feeding conditions and the preparation B.
  • the results of the dissolution rate and membrane permeability of drug X from the standard preparation and the preparation B under the feeding conditions are shown in FIG.
  • the plasma concentration of drug X in the human BE study was higher for the preparation B than for the standard preparation.
  • the dissolution rate was slightly higher in the standard preparation
  • the membrane permeability was slightly higher in the preparation B.
  • the elution rate and membrane permeability results were close to those of the human BE test.
  • Empirical data 4 (Effect of gastric emptying rate) 40 mL (pH 1.6) of simulated gastric juice during fasting and one 25 mg of Persantin tablets were placed in the gastric juice pool 1a of the gastrointestinal chamber 1 of the device shown in FIG. While stirring with the rotary stirrer 7, the fasting concentrated simulated small intestinal juice is placed in the gastrointestinal chamber 1 over 10 minutes (flow rate 6 mL / min), 20 minutes (flow rate 3 mL / min), or 30 minutes (flow rate 2 mL / min). By injecting into, 100 mL of simulated small intestinal juice at the time of fasting at pH 6.5 was prepared.
  • the stirring speed by the rotary stirrer 7 was set to 50 rpm, 100 rpm, or 200 rpm.
  • Octanol which is simulated blood, was injected into the vascular chamber 2 over 10 minutes (2.5 mL / min), 20 minutes (1.25 mL / min), or 30 minutes (0.83 mL / min) to obtain a final volume of 25 mL. ..
  • Concentrated simulated intestinal juice is injected into the gastrointestinal chamber From 1 minute to 120 minutes, simulated gastrointestinal juice and simulated blood are sampled over time, and the concentration of dipyridamole, the active ingredient of Persantin tablets, is measured by high performance liquid chromatography. It was measured. Furthermore, the elution rate of dipyridamole from the tablets at each time point (percentage of the amount of dipyridamole in the simulated gastrointestinal fluid at each time point to the amount of dipyridamole in one tablet) (%) was calculated. In addition, the membrane permeability of dipyridamole at each time point (percentage of the amount of dipyridamole in simulated blood at each time point to the amount of dipyridamole in one tablet) (%) was calculated.
  • the results are shown in FIGS. 13, 14, and 15.
  • the time taken to change the pH of the simulated gastrointestinal fluid in the gastrointestinal chamber from pH 1.6 to 6.5 was 10 minutes in FIG. 13, 20 minutes in FIG. 14, and 30 minutes in FIG.
  • the pH change rate is changed, the drug elution rate and the membrane permeability are changed. Further, the elution rate and membrane permeability of the drug are affected by the stirring rate, but the degree of influence of the stirring rate differs depending on the pH change rate. Since the method and apparatus of the present invention can arbitrarily set the stirring rate and the change rate of pH of the simulated gastrointestinal fluid in the gastrointestinal chamber, oral absorption in various humans with different gastrointestinal movements and gastric emptying rates. It can be seen that the sex can be evaluated accurately.
  • Empirical data 5 (Effect of gastric pH) 40 mL (pH 3.0) of simulated gastric juice during fasting and one 25 mg of Persantin tablets were placed in the gastric juice pool 1a of the gastrointestinal chamber 1 of the device shown in FIG. While stirring with a rotary stirrer 7 at a stirring speed of 100 rpm, the fasting concentrated simulated small intestinal juice was applied for 10 minutes (flow rate 6 mL / min), 20 minutes (flow rate 3 mL / min), or 30 minutes (flow rate 2 mL / min). By injecting into the gastrointestinal chamber 1, 100 mL of simulated small intestinal juice at the time of fasting at pH 6.5 was obtained.
  • Octanol which is simulated blood, was injected into the vascular chamber 2 over 10 minutes (2.5 mL / min), 20 minutes (1.25 mL / min), or 30 minutes (0.83 mL / min) to obtain a final volume of 25 mL. ..
  • Concentrated simulated intestinal juice is injected into the gastrointestinal chamber From 1 minute to 120 minutes, simulated gastrointestinal juice and simulated blood are sampled over time, and the concentration of dipyridamole, the active ingredient of Persantin tablets, is measured by high performance liquid chromatography. It was measured. Furthermore, the elution rate of dipyridamole from the tablets at each time point (percentage of the amount of dipyridamole in the simulated gastrointestinal fluid at each time point to the amount of dipyridamole in one tablet) (%) was calculated. In addition, the membrane permeability of dipyridamole at each time point (percentage of the amount of dipyridamole in simulated blood at each time point to the amount of dipyridamole in one tablet) (%) was calculated.
  • the results are shown in Fig. 16.
  • the drug elution rate and membrane permeability are different from the results shown in FIGS. 13 to 15 when the pH in the gastrointestinal chamber 1 at the start of the test was 1.6. Further, as described above, the elution rate and the membrane permeability of the drug are affected by the pH change rate, but the degree of influence of the pH change rate is also different from the results shown in FIGS. 13 to 15. Since the gastric pH differs depending on the human even during the same fasting, it can be seen that the method and apparatus of the present invention can accurately evaluate the oral absorption in various humans.
  • the method and apparatus of the present invention can accurately predict the absorption of an orally administered preparation in humans, the burden of the human BE test performed when developing a generic drug or changing the design of a preparation is reduced. It is also very useful in that it can evaluate oral absorbability under various conditions.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une méthode d'évaluation d'absorbabilité orale d'un médicament, ladite méthode consistant à placer le médicament ou une préparation contenant un médicament dans un fluide gastro-intestinal simulé, à permettre au médicament se trouvant dans le fluide gastro-intestinal simulé de pénétrer dans du sang simulé à travers une membrane perméable aux médicaments, et ensuite à mesurer la concentration de médicament dans le fluide gastro-intestinal simulé et/ou dans le sang simulé pour ainsi évaluer l'absorbabilité orale du médicament ou du médicament présent dans la préparation après administration orale, caractérisée en ce que les états du fluide gastro-intestinal simulé sont modifiés dans le temps de façon à imiter les conditions présentes dans l'estomac et ensuite les conditions présentes dans l'intestin grêle et, en même temps, la zone de contact entre le fluide gastro-intestinal simulé et la membrane perméable aux médicaments est agrandie dans le temps. La présente méthode permet, après l'administration orale du médicament ou d'une préparation contenant un médicament à un être humain, d'évaluer avec une grande précision l'absorbabilité d'un médicament dans le sang circulant dans tout le corps.
PCT/JP2020/044362 2020-04-22 2020-11-27 Méthode et dispositif d'évaluation d'absorbabilité orale de médicament WO2021215039A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021521458A JP7090272B2 (ja) 2020-04-22 2020-11-27 薬物の経口吸収性評価方法及び装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020076301 2020-04-22
JP2020-076301 2020-04-22

Publications (1)

Publication Number Publication Date
WO2021215039A1 true WO2021215039A1 (fr) 2021-10-28

Family

ID=78270464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/044362 WO2021215039A1 (fr) 2020-04-22 2020-11-27 Méthode et dispositif d'évaluation d'absorbabilité orale de médicament

Country Status (2)

Country Link
JP (1) JP7090272B2 (fr)
WO (1) WO2021215039A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114527246A (zh) * 2022-02-17 2022-05-24 深圳中旭生物科技有限公司 一种心脑血管药物研发检测设备
CN115240875A (zh) * 2022-07-25 2022-10-25 湖南慧泽生物医药科技有限公司 一种药物吸收速率常数的直接估测方法
CN116952856A (zh) * 2023-07-25 2023-10-27 广州新征程生物科技有限公司天津分公司 一种基于大数据的胚胎素丸剂含量高精度检测系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807115A (en) * 1996-01-31 1998-09-15 Hu; Oliver Yoa-Pu Dissolution apparatus simulating physiological gastrointestinal conditions
JP2012037512A (ja) * 2010-08-04 2012-02-23 Rohm & Haas Co 改良された溶出試験装置
JP6386193B2 (ja) * 2014-11-21 2018-09-05 アブソープション システムズ グループ リミテッド ライアビリティ カンパニー 薬物の溶解、吸収及び透過の付随評価のためのシステム、並びに該システムを使用する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807115A (en) * 1996-01-31 1998-09-15 Hu; Oliver Yoa-Pu Dissolution apparatus simulating physiological gastrointestinal conditions
JP2012037512A (ja) * 2010-08-04 2012-02-23 Rohm & Haas Co 改良された溶出試験装置
JP6386193B2 (ja) * 2014-11-21 2018-09-05 アブソープション システムズ グループ リミテッド ライアビリティ カンパニー 薬物の溶解、吸収及び透過の付随評価のためのシステム、並びに該システムを使用する方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114527246A (zh) * 2022-02-17 2022-05-24 深圳中旭生物科技有限公司 一种心脑血管药物研发检测设备
CN115240875A (zh) * 2022-07-25 2022-10-25 湖南慧泽生物医药科技有限公司 一种药物吸收速率常数的直接估测方法
CN115240875B (zh) * 2022-07-25 2023-08-15 湖南慧泽生物医药科技有限公司 一种药物吸收速率常数的直接估测方法
CN116952856A (zh) * 2023-07-25 2023-10-27 广州新征程生物科技有限公司天津分公司 一种基于大数据的胚胎素丸剂含量高精度检测系统
CN116952856B (zh) * 2023-07-25 2024-03-26 广州新征程生物科技有限公司天津分公司 一种基于大数据的胚胎素丸剂含量高精度检测系统

Also Published As

Publication number Publication date
JP7090272B2 (ja) 2022-06-24
JPWO2021215039A1 (fr) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7090272B2 (ja) 薬物の経口吸収性評価方法及び装置
Charalabidis et al. The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS): beyond guidelines
Guerra et al. Development and validation of a new dynamic computer‐controlled model of the human stomach and small intestine
Silva et al. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer
Minekus The TNO gastro-intestinal model (TIM)
Gittings et al. Dissolution methodology for taste masked oral dosage forms
Zahirul et al. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities
Huang et al. In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives
Rezhdo et al. Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement
Baxevanis et al. Fed-state gastric media and drug analysis techniques: Current status and points to consider
Cascone et al. The influence of dissolution conditions on the drug ADME phenomena
Souliman et al. Investigation of the biopharmaceutical behavior of theophylline hydrophilic matrix tablets using USP methods and an artificial digestive system
Van Den Abeele et al. Gastrointestinal and systemic disposition of diclofenac under fasted and fed state conditions supporting the evaluation of in vitro predictive tools
EP2368565B1 (fr) L'enrichissement de pre-beta lipoprotéines haute densité
Naylor et al. Use of a gastro-intestinal model and Gastroplus™ for the prediction of in vivo performance
O'farrell et al. In vitro models to evaluate ingestible devices: Present status and current trends
Shrivas et al. Advances in in vivo predictive dissolution testing of solid oral formulations: how closer to in vivo performance?
CN111435134A (zh) 一种胃肠动态模拟装置
Bogataj et al. Development of a glass-bead device for dissolution testing
Pompa et al. A new gastro-intestinal mathematical model to study drug bioavailability
Hasan et al. A key approach on dissolution of pharmaceutical dosage forms
CN209894783U (zh) 一种胃肠动态模拟装置
Cascone et al. Mimicking the contractions of a human stomach and their effect on pharmaceuticals
Klein Rectal dosage forms
Kakuk et al. Advances in drug release investigations: Trends and developments for dissolution test media

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021521458

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20932330

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20932330

Country of ref document: EP

Kind code of ref document: A1